Table 2. Efficacy of the RTS,S/AS01E Vaccine against Episodes of Clinical Malaria.^*.

Episode		RTS,S/AS01E Vaccine				Rabies Vaccine				Adjusted Efficacy		Unadjusted Efficacy
		No. of Subjects	No. of Episodes	Person-Yr at Risk	Event Rate	No. of Subjects	No. of Episodes	Person-Yr at Risk	Event Rate	% (95% CI)	P Value	% (95% CI)	P Value
According-to-protocol analysis
First or only episode
	>2500 parasites/μl	402	32	245	0.13	407	66	239	0.28	53 (28–69)	<0.001	55 (31–70)	<0.001
	>0 parasites/μl	402	33	245	0.13	407	70	237	0.30	55 (31–70)	<0.001	57 (34–71)	<0.001
All multiple episodes
	>2500 parasites/μl	402	38	254	0.15	407	86	255	0.34	56 (31–72)	<0.001	58 (34–73)	<0.001
	>0 parasites/μl	402	40	254	0.16	407	94	255	0.37	58 (35–73)	<0.001	60 (37–74)	<0.001
Intention-to-treat analysis
First or only episode
	>2500 parasites/μl	447	42	351	0.12	447	78	339	0.23			49 (26–65)	<0.001
	>0 parasites/μl	447	47	349	0.13	447	81	337	0.24			45 (21–62)	0.001
All multiple episodes
	>2500 parasites/μl	447	49	364	0.13	447	107	365	0.29			54 (31–69)	<0.001
	>0 parasites/μl	447	57	364	0.16	447	117	365	0.32			50 (26–67)	<0.001

^*Percentage efficacy was calculated by means of a Cox regression model for the risk of first episodes and a Poisson regression model for multiple episodes. The event rate was calculated by dividing the number of episodes by the person-years at risk. The according-to-protocol analysis was adjusted for the covariates use or nonuse of insecticide-treated net, age, distance from the dispensary, and village; data collection for this analysis began 2 weeks after the last vaccination and ended with the final blood test. The intention-to-treat analysis was unadjusted, and data collection began with the first vaccination and ended with the final blood test.